Your Messages Inbox
Your Article Summary
See Latest ArticlesPhase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies
Journal of Clinical Oncology, 09/04/09
Wong C–I et al. – ABT–869 by continuous once–daily dosing was tolerable at doses <=0.25 mg/kg/d. Biomarker evidence of antiangiogenic activity and DCE–MRI evidence of tumor antiangiogenesis were observed together with promising clinical activity.
Related Articles
Eruptive Keratoacanthoma-Type Squamous Cell Carcinomas in Patients Taking Sorafenib for the Treatment of Solid Tumors
Dermatologic Surgery, 11/17/09
Relevance Score: 80%
Early prediction of success or failure using second generation tyrosine kinase inhibitors for chronic myeloid leukemia
Haematologica, 10/21/09
Relevance Score: 79%
Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different
Anti-Cancer Drugs, 10/19/09
Relevance Score: 79%
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
Journal of Clinical Oncology, 10/16/09
Relevance Score: 79%
Small, Mobile Fc[epsilon]RI Receptor Aggregates Are Signaling Competent
Immunity, 10/01/09
Relevance Score: 79%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Amgen, 12/10/09
Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Repligen, 12/10/09
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/10/09
Article Search
Sponsor